4-(4-硝基苄基)哌啶 | 77093-81-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-(4-硝基苄基)哌啶
• 英文名称: 4-(4'-nitrobenzyl)piperidine
• 英文别名: 4-(4-Nitrobenzyl)piperidine；4-[(4-nitrophenyl)methyl]piperidine
• CAS: 77093-81-3
• 化学式: C₁₂H₁₆N₂O₂
• 分子量: 220.271
• InChiKey: AVWJNEWPWOHGRY-UHFFFAOYSA-N

物化性质

• 沸点：
  372.1±22.0 °C(Predicted)
• 密度：
  1.143±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  57.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(4-硝基苄基)哌啶 在 potassium phosphate 、 potassium carbonate 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 36.5h， 生成 1-[4-[(4-Nitrophenyl)methyl]piperidin-1-yl]-2-[11-[2-[4-[(4-nitrophenyl)methyl]piperidin-1-yl]-2-oxoethyl]-3,11,17,18-tetrazatricyclo[11.3.1.15,9]octadeca-1(17),5(18),6,8,13,15-hexaen-3-yl]ethanone
  参考文献：
  名称：

  [EN] NEW 2, 1 L -DIAZA-[3.3](2,6)PYRIDINOPHANE COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI CONTRAST AGENTS AND 52MN BASED PET CONTRAST AGENTS
  [FR] NOUVEAUX COMPOSÉS 2, 1 L-DIAZA-[3,3](2,6)PYRIDINOPHANE ET LEUR APPLICATION COMME LIGANDS D'AGENTS DE CONTRASTE IRM À BASE DE D'IONS MÉTALLIQUES ESSENTIELS ET D'AGENTS DE CONTRASTE TEP À BASE DE 52MN

  摘要：

  本发明的一个主题是通式（I）的化合物，它们的异构体，其生理上可接受的盐和/或Mn（II），Fe（II），Fe（III），Co（II）和Ni（II）配合物。本发明的另一个主题是上述化合物的应用。通式（I）的化合物：其中-NRR1基团可能指：a）-NRR1中带有环中的N原子意味着一个由4至7个环组成的环，在某些情况下可能含有另一个杂原子，并且在特定情况下该环可能被取代为一个芳基（由5至7个碳原子）取代为-COOH，-OH，-OCH3，-NO2，-NH2，-NCS，-NHS-活化酯，芳基（由5至7个碳原子），或硝基，氨基或异硫氰酸酯基团，或b）在-NRR1基团中R表示H原子，烷基，芳基，硝基芳基，氨基芳基或异硫氰酸酯芳基（由1至6个碳原子）和R4是H原子，烷基（由1至6个碳原子）或-(CH2)n-COOH基团，其中n=1至10的整数，或c）-NRR1基团是以下基团之一：（式II）其中R2是H原子，羧基或烷基羰基基团（由1至4个碳原子）；（式III）且R2是H原子或烷基或芳基（由1至6个碳原子）基团，X分别独立于H原子，-CH3，-COOH，-OH，-OCH3，烷氧基（由2至6个碳原子），-NO2，-NH2，-NCS，-NHS-活化酯，烷基（由2至12个碳原子）或芳基（由5至7个碳原子）基团，在某些情况下后者可能被取代为羟基，羟基烷基（由1至6个碳原子），硝基，氨基或异硫氰酸酯基团。

  公开号：

  WO2017089848A1
• 作为产物：
  描述：

  哌啶,4-[(4-硝基苯基)甲基]-1-(三氟乙酰基)- 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 以61%的产率得到4-(4-硝基苄基)哌啶
  参考文献：
  名称：

  Reactive derivatives for affinity labeling in the ifenprodil site of NMDA receptors

  摘要：

  To prepare thiol-reactive ifenprodil derivatives designed as potential probes for cysteine-substituted NR2B containing NMDA receptors, electrophilic centers were introduced in different areas of the ifenprodil structure. Intermediates and final compounds were evaluated by binding studies and by electrophysiology to determine the structural requirements for their selectivity. The reactive compounds were further tested for their stability and for their reactivity in model reactions; some were found suitable as structural probes to investigate the binding site and the docking mode of ifenprodil in the NR2B subunit. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.04.019

文献信息

• [EN] 1- (2H-PYRAZOL -3-YL) -3YL) {4-`1- (BENZOYL) -PIPERIDIN-4-YLMETHYL!-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF IMFLAMMATIONS<br/>[FR] DERIVES DE 1-(2H-PYRAZOL-3-YL)-3-{4-`1-(BENZOYL)-PIPERIDIN-4-YLMETHYL!-PHENYL}-UREE ET COMPOSES ASSOCIES UTILISES COMME INHIBITEURS DE LA KINASE P38 ET/OU COMME INHIBITEURS DU FACTEUR DE NECROSE TUMORALE (TNF) DANS LE TRAITEMENT DES INFLAMMATIONS
  申请人：AVENTIS PHARMA INC

  公开号：WO2004100946A1

  公开（公告）日：2004-11-25

  The present invention provides compounds of Formula (I) Wherein ( ) is an optional ethylene bridge; R1 is alkyl, cycloalkyl, aryl or aryl substituted with one or more substituents selected from alkyl, alkoxy and amino, or R1 is pyridyl or pyridyl substituted with one or more substituents selected from alkyl, alkoxy and amino; R2 is optionally substituted alkyl, alkoxyalkyl, optionally substituted cycloalkylalkyl, arylalkyl, or R2 is arylalkyl substituted with one or more substituents selected from alkyl, alkoxy; X is -C(O)-, -C(O)-CH2-, -S(O)2-, or NH-C(O)- ; and A is optionally substituted alkyl or other substituents as defined in claim 1. Pharmaceutical compositions comprising such compounds, their preparation, and their pharmaceutical use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and/or tumor necrosis factor (TNF), such as asthma or joint inflammation.

  本发明提供了Formula (I)的化合物，其中( )是可选的乙烯桥；R1是烷基、环烷基、芳基或芳基，其上取代基可为烷基、烷氧基和氨基中的一种或多种，或者R1是吡啶基或吡啶基，其上取代基可为烷基、烷氧基和氨基中的一种或多种；R2是可选取代的烷基、烷氧基烷基、可选取代的环烷基烷基、芳基烷基，或者R2是芳基烷基，其上取代基可为烷基、烷氧基中的一种或多种；X是-C(O)-、-C(O)-CH2-、-S(O)2-或NH-C(O)-；A是可选取代的烷基或其他在权利要求1中定义的取代基。包括这些化合物的药物组合物、其制备以及在治疗能够通过抑制p38激酶和/或肿瘤坏死因子(TNF)调节的疾病状态中的药用，如哮喘或关节炎。
• [EN] NEW 6-OXA-3,9, 15-TRIAZA-BICYCLO[9.3.1 ]PENTADEC A- 1 ( 14), 1 1 ( 15), 12-TRIENE DERIVATIVES BASED COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI AND 52MN BASED PET CONTRAST AGENTS<br/>[FR] NOUVEAUX COMPOSÉS À BASE DE DÉRIVÉS DE 6-OXA-3,9,15-TRIAZA-BICYCLO[9.3.1]PENTADÉCA-1(14),11(15),12-TRIENE ET LEUR APPLICATION À TITRE DE LIGANDS D'AGENTS DE CONTRASTE IRM ESSENTIELS À BASE D'IONS MÉTALLIQUES ET D'AGENTS DE CONTRASTE PET ESSENTIELS À BASE DE 52MN
  申请人：DEBRECENI EGYETEM

  公开号：WO2017089849A1

  公开（公告）日：2017-06-01

  The one subject of the invention is the compounds of general formula (I), their isomers, their physiologically acceptable salts and/or Mn(ll), Fe(ll), Fe(lll), Co(ll) and Ni(ll) complexes and their application: where R1| = - OH or -NR 3 R 4 amide functionality

  本发明的一个主题是一般式(I)的化合物，它们的异构体，它们的生理上可接受的盐和/或Mn(ll)、Fe(ll)、Fe(lll)、Co(ll)和Ni(ll)配合物及其应用：其中R1| = - OH或-NR 3 R 4 酰胺官能团
• [EN] NEW 3,6,9, 15-TETRAAZA-BICYCLO [9.3.1 ]PENTADECA- 1(14), 11(15), 12-TRIENE BASED COMPOUNDS AND THEIR APPLICATION AS LIGANDS OF ESSENTIAL METAL ION BASED MRI AND 52MN BASED PET CONTRAST AGENTS<br/>[FR] NOUVEAUX COMPOSÉS À BASE DE 3,6,9,15-TÉTRAAZA-BICYCLO [9.3.1]PENTADÉCA-1(14),11(15),12-TRIÈNE ET LEUR APPLICATION COMME LIGANDS D'AGENTS DE CONTRASTE POUR IRM À BASE D'IONS MÉTALLIQUES ET POUR TEP À BASE DE 52MN
  申请人：DEBRECENI EGYETEM

  公开号：WO2017089847A1

  公开（公告）日：2017-06-01

  The one subject of the invention is the compounds of general formula (I), their isomers, their physiologically acceptable salts and/or Mn(II), Fe(II), Fe(III), Co(II) and Ni(II) complexes. The other subject of the invention is the application of the above compounds. The compounds of general formula (I): wherein Ra refers to -OH group or -NR3R4 group and -NR3R4 group may refer to: a) -NR3R4 with N atom in the ring means a ring of 4 to 7, that in certain cases may contain another heteroatom, and in specific cases the ring may be replaced with an aryl group (of 5 to 7 carbon atoms) substituted with -COOH, -OH, -OCH3, -NO2, -NH2, -NCS, -NHS- activated ester, aryl (of 5 to 7 carbon atoms), or nitro-, amino- or isothiocyanate group, or b) in the -NR3R4 group R3 means a H atom, alkyl, aryl, nitroaryl, aminoaryl or isothiocyanate-aryl group (of 1 to 6 carbon atoms) and R4 is a H atom, alkyl (of 1 to 6 carbon atoms) or -(CH2)n-COOH group, whereas n=1 to 10 integer, or c) -NR3R4 group is one of the below groups: whereas R1 is a H atom, carboxyl or alkyl-carbonyl group (of 1 to 4 carbon atoms); and Rb is a H atom or alkyl group (of 1 to 6 carbon atoms), and X means independently from one another H atom, -CH3, -COOH, -OH, -OCH3, alkoxy- (of 2 to 6 carbon atoms), -NO2, -NH2, -NCS, -NHS-activated ester, alkyl (of 2 to 12 carbon atoms) or aryl (of 5 to 7 carbon atoms) group, in certain cases the latter may be substituted with hydroxyl, hydroxyalkyl (of 1 to 6 carbon atoms), nitro, amino or isothiocyanate group; and Y means: -NH- or >NCH2-Z group, whereas in the >CH2-Z group Z refers to one selected group of the below: -C(O)NR3R4 group, in which -NR3R4 means as referred to above, whereas z= 0- 18 integer, whereas z=0-18 integer, whereas z=0-18 integer, whereas z=0-18 integer and H atom, alkyl (of 1 to 6 carbon atoms) or -(CH2)n-COOH group, whereas n=l to 10 integer, or, whereas z= 0-18 integer, whereas z=0-18 integer and R2a refers to H atom, -OCH3, or -CF3 group, whereas R2b refers to H atom, -CH3, -OCH3>.CF3; - COOH, -COON(CO)2(CH2)2, -NO2, -NH2 or -NCS- group, whereas z= 0-18 integer and R2c refers to H atom, NO2, -NH2 or -NCS- group, whereas ζ=0-18, -and x=l-5 integer, whereas z=0-18,, and x=1.5 integer; whereas z=1-5, and x=1-5 integer, R2d refers to H atom, -CH3, -OCH3;.CF3, -COOH, - COON(CO)2(CH2)2, -NO2, -NH2 or -NCS group,

  本发明的一个主题是通式（I）的化合物，它们的异构体，它们的生理可接受的盐和/或Mn（II），Fe（II），Fe（III），Co（II）和Ni（II）络合物。该发明的另一个主题是上述化合物的应用。通式（I）的化合物：其中Ra代表-OH基团或-NR3R4基团，而-NR3R4基团可能指：a）-NR3R4，环中的N原子表示4至7的环，在某些情况下可能含有另一个杂原子，并且在特定情况下环可能被取代为芳基（5至7个碳原子）取代为-COOH，-OH，-OCH3，-NO2，-NH2，-NCS，-NHS-活化酯，芳基（5至7个碳原子），或硝基，氨基或异硫氰酸酯基团，或b）在-NR3R4基团中，R3表示H原子，烷基，芳基，硝基芳基，氨基芳基或异硫氰酸酯芳基（1至6个碳原子），而R4是H原子，烷基（1至6个碳原子）或-(CH2)n-COOH基团，其中n=1至10整数，或c）-NR3R4基团是以下基团之一：其中R1是H原子，羧基或烷基羰基基团（1至4个碳原子）；而Rb是H原子或烷基基团（1至6个碳原子），X分别独立于H原子，-CH3，-COOH，-OH，-OCH3，烷氧基（2至6个碳原子），-NO2，-NH2，-NCS，-NHS-活化酯，烷基（2至12个碳原子）或芳基（5至7个碳原子）基团，在某些情况下后者可能被羟基，羟基烷基（1至6个碳原子），硝基，氨基或异硫氰酸酯基团取代；而Y表示：-NH-或>NCH2-Z基团，其中在>NCH2-Z基团中，Z指下列选定的基团之一：-C（O）NR3R4基团，其中-NR3R4如上所述，其中z=0-18整数，其中z=0-18整数，其中z=0-18整数，其中z=0-18整数和H原子，烷基（1至6个碳原子）或-(CH2)n-COOH基团，其中n=1至10整数，或，其中z=0-18整数，其中z=0-18整数，其中R2a指H原子，-OCH3，或-CF3基团，而R2b指H原子，-CH3，-OCH3>.CF3；-COOH，-COON（CO）2（CH2）2，-NO2，-NH2或-NCS-基团，其中z=0-18整数，而R2c指H原子，NO2，-NH2或-NCS-基团，而ζ=0-18，-和x=1-5整数，其中z=0-18，，和x=1.5整数；其中z=1-5，，和x=1-5整数，R2d指H原子，-CH3，-OCH3；.CF3，-COOH，-COON（CO）2（CH2）2，-NO2，-NH2或-NCS基团。
• Subtype-selective NMDA receptor ligands and the use thereof
  申请人：Warner-Lambert Co.

  公开号：US06218404B1

  公开（公告）日：2001-04-17

  The invention relates to subtype-selective NMDA receptor ligands and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neuro-degenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, Parkinson's disease, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.

  该发明涉及亚型选择性NMDA受体配体及其用于治疗或预防与中风、缺血、中枢神经系统创伤、低血糖和手术相关的神经元丢失，以及治疗包括阿尔茨海默病、肌萎缩性侧索硬化、亨廷顿病和唐氏综合征在内的神经退行性疾病，治疗或预防兴奋性氨基酸过度刺激的不良后果，治疗焦虑、精神病、抽搐、氨基糖苷类抗生素引起的听力损失、偏头痛、慢性疼痛、帕金森病、青光眼、巨细胞病毒性视网膜炎、尿失禁、阿片类药物耐受性或戒断症状，并诱导麻醉，以及增强认知能力。
• Pyrazoles as inhibitors of tumor necrosis factor
  申请人：Borcherding R. David

  公开号：US20060063796A1

  公开（公告）日：2006-03-23

  The present invention provides compounds of Formula (I) and ester prodrugs, pharmaceutically acceptable salts or solvates of such compounds; or ester prodrugs of such salts or solvates; pharmaceutical compositions comprising such compounds, their preparation, and their pharmaceutical use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and/or tumor necrosis factor (TNF).

  本发明提供了式（I）的化合物和酯前药、这些化合物的药学上可接受的盐或溶剂；或这些盐或溶剂的酯前药；包括这些化合物的制药组合物，其制备以及它们在治疗能够通过抑制p38激酶和/或肿瘤坏死因子（TNF）调节的疾病状态中的药物应用。